>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
Measured by its binding ability in a functional ELISA. When Recombinant Mouse LILRC1 (Catalog # 9288-T4) is coated at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED50 = 60-360 ng/mL.
Mouse myeloma cell line, NS0-derived Gln17-Asn248, with a C-terminal 6-His tag
When Recombinant Mouse LILRC1 (Catalog # 9288-T4) is coatedat 2 µg/mL, Recombinant Human Angiopoietin-likeProtein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED50 = 60-360 ng/mL.
The leukocyte immunoglobulin-like receptors (LILR) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIRs) (1). LILRA5, also known as ILT11, LIR-9, CD85f, and LILRC1, consists of a 227 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 10 aa cytoplasmic tail (2, 3). The ECD contains two Ig-like domains (4), and the transmembrane segment contains a positively charged aspartic acid residue which may mediate its association with the signaling molecule, FcR common gamma chain (3, 5). Within the ECD, mouse LILRA5 shares 56% and 85% aa sequence identity with human and rat LILRA5, respectively. LILRA5 is expressed by monocytes, macrophages, and neutrophils (2, 3, 5). It is found as an approximately 40 kDa molecule on the cell surface, while a soluble 25 kDa form can be released into the synovial fluid of rheumatoid arthritis patients (2, 5). Cross-linking of LILRA5 on monocytes induces the expression of pro-inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha) as well as the anti-inflammatory IL-10 (2, 5). R&D Systems in-house testing indicates that LILRA5 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (6).
Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
Borges, L. et al. (2003) Blood 101:1484.
Hoelsbrekken, S.E. et al. (2005) Immunogenetics 57:479.
Shiroishi, M. et al. (2006) J. Biol. Chem. 281:19536.
Mitchell, A. et al. (2008) Eur. J. Immunol. 38:3459.